Murali Ramachandra

Murali Ramachandra

Company: Aurigene Discovery Technologies

Job title: Chief Executive Officer


Discussing an Oral Immune Checkpoint Antagonist Dually Targeting TIGIT & PD-1 Pathways for Cancer Therapy 11:00 am

• Identifying an orally bioavailable dual TIGIT and PD-L1 inhibitor • The compound shows potent rescue of PVR-mediated inhibition of IL-2 and IFN-γ production from T-cells and PD-L1 mediated PBMC proliferation • Discovering that in syngeneic tumor models, upon oral administration the compound shows excellent tumor distribution and exhibits profound anti-tumor activity coupled with immune…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.